ClinicalTrials.gg
RecruitingNCT07502560Updated May 12, 2026

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

A Phase 4 interventional study of Recombinant zoster vaccine and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Recruiting at 8 sites in Finland. Open to participants aged 76 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33,609
Allocation
Randomized
Ages
76 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Planned enrollment
2nd of 46
33,609 · median 239
Started
2026
with 2 others
Phase 4
8 of 46
4 open now
Primary completion
2030-04
later than 10 of 10 live
Registered
46th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 4, reaches primary completion later than 10 of the 10 other live ones, and was the 46th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 76 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

03

Conditions studied

  • Herpes Zoster

Keywords

  • Recombinant Zoster Vaccine
  • Shingrix
  • Herpes Zoster
  • Incident dementia
  • Alzheimer's Disease
  • Older adults
  • Finland
04

Who can participate

Ages eligible
76 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Citizens living permanently in Finland, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed obtained from the participant prior to performance of any study-specific procedure. Informed consent will include consent to access health register data for participants.
  • Age 76 years or older at the time of signing the informed consent.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a Herpes Zoster (HZ) vaccine.
  • History of dementia diagnosis prior to enrolment, including confirmed cases or those under investigation. This includes:

    • History of a confirmed clinical diagnosis of dementia prior to enrolment.
    • Prior or current use of medications intended to treat dementia.
    • Current or recent history of cognitive assessments for any memory deficit or suspected dementia before enrolment including investigations that are ongoing or that were inconclusive (but not those for which dementia was conclusively ruled out); mild cognitive impairment on its own without any other information to indicate cognitive decline or dementia will not result in exclusion.
  • Severely individuals.
  • Concurrently participating in another clinical trial, in which the participant has been or will be exposed to an product or ongoing participation in trials focused on preventive dementia interventions.
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.
  • Living in a nursing facility.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33,609 participants (estimated)

Study arms

  • Experimental
    Recombinant zoster vaccine Group

    Participants in this group receive recombinant zoster vaccine, the first dose being administered at Visit 1 (Day 1) and the second dose at Visit 2 (between 2 and 6 months after the first dose), according to the approved recombinant zoster vaccine dosing schedule.

    Biological: Recombinant zoster vaccine

  • Placebo comparator
    Placebo Group

    Participants in this group receive placebo, the first dose being administered at Visit 1 (Day 1) and the second dose at Visit 2 (between 2 and 6 months after the first dose).

    Drug: Placebo

Interventions

  • Recombinant zoster vaccine administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose), according to the approved recombinant zoster vaccine dosing schedule.

    Also known as: Shingrix

  • DrugPlacebo

    Placebo administered intramuscularly, one dose at Visit 1 (Day 1) and one dose at Visit 2 (between 2 and 6 months after the first dose).

06

What researchers measure

Primary outcomes

  1. Hazard ratio of incident dementia diagnosis

    Dementia diagnosis is defined as the first-time diagnosis of dementia as identified during the follow-up period.

    Time frame: From first dose of study intervention (Day 1) until the date of first dementia diagnosis, death, loss to follow-up, or end of data availability, whichever occurs first, assessed up to 10 years

Secondary outcomes

  1. Hazard ratio of incident dementia diagnosis

    Dementia diagnosis is defined as the first-time diagnosis of dementia as identified during the follow-up period.

    Time frame: From 1 month after second dose of study intervention (2 to 6 months after first dose of study intervention) until the date of first dementia diagnosis, death, loss to follow-up, or end of data availability, whichever occurs first, assessed up to 10 years

  2. Hazard ratio of incident Alzheimer's disease diagnosis

    Alzheimer's disease diagnosis is defined as the first-time diagnosis of Alzheimer's disease as identified during the follow-up period.

    Time frame: From first dose of study intervention (Day 1) until the date of first Alzheimer's disease diagnosis, death, loss to follow-up, or end of data availability, whichever occurs first, assessed up to 10 years

07

Study locations

8 of 8 sites recruiting
  • GSK Investigational Site
    Espoo, 02230, Finland
    Recruiting
  • GSK Investigational Site
    Helsinki, 00100, Finland
    Recruiting
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
    Recruiting
  • GSK Investigational Site
    Kokkola, 67100, Finland
    Recruiting
  • GSK Investigational Site
    Oulu, 90220, Finland
    Recruiting
  • GSK Investigational Site
    Seinäjoki, 60100, Finland
    Recruiting
  • GSK Investigational Site
    Tampere, 33100, Finland
    Recruiting
  • GSK Investigational Site
    Turku, 20520, Finland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · d3l8i7lo48obsd.cloudfront.net

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2030, 48 months after the start.

Of 19 phase 4 interventional studies under Herpes Zoster, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 31, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Apr 1, 2030
CompletionEst.
Mar 31, 2037
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502560
Lead sponsor
GlaxoSmithKline
Collaborators
Finnish Vaccine Research;, Dr Arto Palmu
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Mar 31, 2026
Primary completion
Apr 1, 2030 (estimated)
Completion
Mar 31, 2037 (estimated)
Last update
May 12, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion